REG - Venture Life Group - Director/PDMR Shareholding

Venture LifeAnnouncement

21/02/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200221:nRSU6611Da

RNS Number : 6611D  Venture Life Group PLC  21 February 2020

21 February 2020

Venture Life Group plc

("Venture Life" the "Company" or the "Group")

Director/PDMR Shareholding

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the international self-care market, announces
that, following his son's eighteenth birthday, Group CEO, Jerry Randall's
beneficial interest in ordinary shares of 0.3 pence each of the capital of the
Company ("Ordinary Shares") has reduced by 141,000 Ordinary Shares.
Accordingly, Jerry Randall now has a beneficial interest in 3,769,729 Ordinary
Shares, representing approximately 4.5 per cent. of the Group's issued share
capital.

 

For further information, please contact:

 Venture Life Group PLC                                                        +44(0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Cenkos Securities plc (Nomad and Broker)                                      +44(0)20 7397 8900
 Mark Connelly / Stephen Keys / Cameron MacRitchie (Corporate Finance)
 Russell Kerr / Michael Johnson (Sales)

  Alma PR
+44(0)20 3405 0208
   Rebecca Sanders-Hewett / Hilary Buchanan / Helena Bogle / Jessica Joynson

 

 About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in both the UK and Italy, the Group's
product portfolio includes some key products such as the UltraDEX and Dentyl
oral care product ranges, food supplements for maintaining brain function,
medical devices for women's intimate healthcare and proctology and
dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK these are supplied direct by the company, outside of the
UK they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the
Group also provides development and manufacturing services to companies in the
medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  DSHFLFIRFTIIFII